AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05809154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Video-Urodynamics
Description: Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
Study NCT01931202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
Study NCT01931202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
Study NCT04124718 — intervention group
Intervention type: GENETIC
Intervention: high caries experience
Description: DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
Study NCT03230929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS-PLE
Description: Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
Study NCT03773055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPC-06
Description: Patients will receive once a day for 7 days.
Study NCT03398408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
Study NCT04433520 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder
Description: Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder.
Study NCT04433520 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder
Description: Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder.
Study NCT03356847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of ocular implant
Description: Removal of natural lens and replacement with a SISA monofocal intraocular implant
Study NCT02267499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLM training
Description: Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
Study NCT02672956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ten mm trocar
Study NCT01522651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Tablets administered orally twice daily.
Study NCT01522651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Capsule administered orally twice daily
Study NCT01522651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine placebo
Description: Tablets administered orally twice daily.
Study NCT01522651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranolazine placebo
Description: Tablets administered orally twice daily.
Study NCT01522651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronedarone placebo
Description: Capsules administered orally twice daily
Study NCT01522651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone placebo
Description: Capsules administered orally twice daily
Study NCT00754429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan 50mg qd for 30 weeks.
Study NCT00754429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5 mg q.d for 30 weeks.
Study NCT04143971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intermittent fasting diet
Description: intermittent fasting diet
Study NCT04143971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low calorie diet
Description: continuous low calorie diet
Study NCT03964415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
Study NCT03964415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C and Mosaic gp140 HIV bivalent vaccine
Description: Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
Study NCT03964415 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo.
Study NCT03829189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: prebiotic supplement
Study NCT03829189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: placebo supplement
Study NCT00744055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: prazosin (16mg/day) 2 times a day
Study NCT00744055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02144220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual care visit
Description: Video-conferencing visit with a Parkinson disease specialist
Study NCT01198418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Internet-based intervention that assesses transmission risk and provides prevention messages
Study NCT03201653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stump closure using NU-KNIT SURGICEL
Description: We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
Study NCT03201653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stump closure using NU-KNIT SURGICEL
Description: We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
Study NCT01662973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional plus UC-MSC treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1\*10E6 UC-MSC/kg body weight for 12 weeks.
Study NCT01662973 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional plus placebo treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
Study NCT01628991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioural program
Description: interventional behavioural program
Study NCT01628991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iranian version of vaginal cones
Description: intravaginal device(vaginal cone) for promote the pelvic floor exercises
Study NCT01052012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine
Description: Injectable Extended Release Solution; SABER-Bupivacaine /Once
Study NCT01052012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Injectable Solution; Bupivacaine HCl /Once
Study NCT01052012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SABER-Placebo
Description: Injectable Solution; SABER-Placebo/Once
Study NCT04250493 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Homeostasis Model Assessment of insulin resistance (HOMA)
Description: Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
Study NCT04250493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Homeostasis Model Assessment of insulin resistance (HOMA)
Description: Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index
Study NCT04250493 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MOntreal Cognitive Assessment (MoCA)
Description: Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
Study NCT04250493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOntreal Cognitive Assessment (MoCA)
Description: Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)
Study NCT04806763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menicon Z Night
Description: To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children
Study NCT04806763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Distance, single-vision glasses were used as control
Study NCT01873391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic hysteroscopy
Study NCT00754559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8mg/kg iv every 4 weeks
Study NCT03576820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
Study NCT03576820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
Study NCT03890107 — intervention group
Intervention type: DEVICE
Intervention: OtoSight Middle Ear Scope
Description: OtoSight imaging using a near-infrared laser
Study NCT02100644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine tablets 25/100 mg
Description: Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
Study NCT04107285 — intervention group
Intervention type: BEHAVIORAL
Intervention: neurocognitive evaluations
Description: The test battery consists of validated and reliable measures of attention, executive functions and memory.
Study NCT04107285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: brain MRIs
Description: Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
Study NCT04107285 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
Study NCT00540761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI imaging
Description: Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
Study NCT03773055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-06
Description: Patients will receive once a day for 7 days.
Study NCT02501811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSC)
Description: 15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Study NCT02501811 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: c-kit+ cells
Description: 15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Study NCT02501811 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Plasmalyte A)
Description: 15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Study NCT02997202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: oral
Study NCT02997202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03615664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine (B) 90 mg/m2 i.v. day 1, 2
Study NCT03615664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
Study NCT03615664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
Study NCT03615664 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~* in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~* in case of SMD - exclusion from the trial~* in case of PMD - exclusion from the trial
Study NCT03615664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Description: Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT.
Study NCT02359968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: radiochemotherapy before surgery
Study NCT02359968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CarboP-pacliT
Description: radiochemotherapy before surgery
Study NCT03248479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously
Study NCT03248479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously
Study NCT02531542 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography according to the READ method.
Description: * Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~* A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels.
Study NCT00001481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Study NCT00001481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Study NCT00001481 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Study NCT00001481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Study NCT00001481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Study NCT04250493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical characteristics of AMS patients
Description: Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)
Study NCT04250493 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain Magnetic Resonance Imaging (MRI)
Description: Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
Study NCT04250493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging (MRI)
Description: Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume
Study NCT04250493 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Optional blood sampling for the constitution of a biological collection
Study NCT04250493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Optional blood sampling for the constitution of a biological collection
Study NCT03083951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete mesocolon excision
Description: Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
Study NCT03083951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional locoregional lymphadenectomy
Description: Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
Study NCT03471676 — intervention group
Intervention type: OTHER
Intervention: Muscular oximetry
Description: 6 minutes walking test performed in the routine medical care with muscle oximetry recording
Study NCT04284917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carglumic Acid (Carbaglu®)
Description: A. Study period: 24 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12. (Check Plasma Amino Acid Analysis, Ammonia, acylcarnitine profile, Urinary organic acid analysis.)~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis will be recorded during treatment period.
Study NCT00800033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
Study NCT00800033 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise training
Description: Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
Study NCT00800033 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pulse based diet
Description: Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
Study NCT05500131 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observation
Description: Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe.
Study NCT01724320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX008
Description: OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day